PFA results for the quarter & half year ended 30.09.2025
Awaiting price reaction for this filing.
The company, now renamed MPS Pharmaa Limited, reported zero revenue from operations for both Q2 FY26 and H1 FY26, with total income of just Rs 0.40 lakh in Q2 and Rs 4.77 lakh in H1 (largely other income). It posted a loss after tax of Rs 22.02 lakh in Q2 and Rs 44.03 lakh in H1, with EPS of (Rs 0.12) and (Rs 0.23) respectively. The company has effectively ceased manufacturing while it awaits renewal of its drug manufacturing licence from the FDA Panchkula and is exploring new buyers and deals to restart operations. BSE has suspended normal trading in the stock (trade-for-trade once a week) due to unpaid annual listing fees since FY22. Net worth has eroded to Rs 64.54 lakh while borrowings stand at Rs 750.55 lakh, and cash on hand is only Rs 0.43 lakh.
This is a deeply distressed small-cap pharma company with no operating revenue, negative equity, and extremely high debt against virtually no cash, posing significant going-concern risk for shareholders. The auditor's qualified review and emphasis-of-matter note, combined with BSE trading restrictions, signal very poor near-term prospects and continued erosion of shareholder value.